Perceptive Advisors LLC Prothena Corp Public LTD CO Transaction History

Perceptive Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$47.3 - $70.6 $898,700 - $1.34 Million	-19,000 Reduced 10.29%	165,615 $7.99 Million
Q2 2023 Aug 14, 2023	SELL	$48.26 - $78.59 $2.56 Million - $4.17 Million	-53,031 Reduced 22.32%	184,615 $12.6 Million
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $397,974 - $496,990	7,646 Added 3.32%	237,646 $14.3 Million
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $5.79 Million - $13.9 Million	230,000 New	230,000 $13.9 Million
Q2 2022 Aug 15, 2022	SELL	$22.73 - $39.98 $1.48 Million - $2.6 Million	-65,144 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$30.27 - $49.22 $1.06 Million - $1.72 Million	-34,856 Reduced 34.86%	65,144 $2.38 Million
Q2 2021 Aug 16, 2021	BUY	$21.63 - $57.65 $2.16 Million - $5.77 Million	100,000 New	100,000 $5.14 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $698M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.